AbbVie (ABBV) Cash from Investing Activities (2012 - 2026)

AbbVie has disclosed Cash from Investing Activities across 15 years of filings, most recently posting -$574.0 million for Q1 2026.

• In Q1 2026, Cash from Investing Activities rose 21.9% year-over-year to -$574.0 million; the TTM figure through Mar 2026 stood at -$6.5 billion (up 45.83% YoY), while the FY2025 annual figure was -$6.6 billion, up 68.09% from the prior year.
• Cash from Investing Activities rose to -$574.0 million in Q1 2026, from -$1.5 billion in the prior quarter.
• Over the last five years, Cash from Investing Activities for ABBV reached as high as $1.3 billion in Q3 2022 and fell as low as -$9.6 billion in Q1 2024.
• The 5-year median for Cash from Investing Activities is -$800.0 million (2023), against an average of -$1.8 billion.
• Annual changes were most pronounced in 2022 — Cash from Investing Activities surged 309.11% — and 2024, when it plunged 2137.4%.
• A 5-year view of Cash from Investing Activities shows it stood at -$448.0 million in 2022, then sank by 78.57% to -$800.0 million in 2023, then tumbled by 134.25% to -$1.9 billion in 2024, then increased by 21.93% to -$1.5 billion in 2025, then soared by 60.77% to -$574.0 million in 2026.
• According to Business Quant data, Cash from Investing Activities over the past three periods registered -$574.0 million, -$1.5 billion, and -$3.3 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.